Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[CAPRICORN and COPERINUS studies].

Y Juillière1

  • 1Département de cardiologie, CHU Nancy-Brabois, allée du Morvan, 54500 Vandoeuvre-les-Nancy.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|April 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Myocarditis and COVID-19, myth or fact?]

Archives des maladies du coeur et des vaisseaux. Pratique·2020
Same author

Response by Robert et al. to the letter regarding article "Time trends in hospital admissions and mortality due to abdominal aortic aneurysms in France, 2002-2013".

International journal of cardiology·2017
Same author

Time trends in hospital admissions and mortality due to abdominal aortic aneurysms in France, 2002-2013.

International journal of cardiology·2017
Same author

[Editorial].

Presse medicale (Paris, France : 1983)·2016
Same author

[New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?].

Annales de cardiologie et d'angeiologie·2016
Same author

Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation.

International journal of cardiology·2012
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Betablocker treatment with carvedilol significantly reduces morbidity and mortality in patients with left ventricular dysfunction post-infarction and in stable severe cardiac insufficiency. This therapy is now a key component in managing heart failure alongside ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular dysfunction and severe cardiac insufficiency are significant clinical challenges.
  • Established treatments for heart failure have limitations.

Purpose of the Study:

  • To evaluate the efficacy of carvedilol in new indications.
  • To assess the impact of carvedilol on morbidity and mortality.

Main Methods:

  • The CAPRICORN and COPERNICUS studies investigated carvedilol's effects.
  • Patient populations included post-myocardial infarction with left ventricular dysfunction and stable severe cardiac insufficiency.

Main Results:

  • Carvedilol demonstrated significant benefits in the studied patient groups.
  • A notable reduction in morbidity and mortality was observed with carvedilol therapy.

Related Experiment Videos

Conclusions:

  • Carvedilol is a significant therapeutic option for post-infarction left ventricular dysfunction and severe cardiac insufficiency.
  • Carvedilol complements existing treatments like angiotensin-converting enzyme inhibitors for heart failure management.